Dynavax Technologies Corp.

Dynavax Technologies Corp. is a commercial-stage biopharma focused on hepatitis B vaccines. Its product HEPLISAV‑B, along with CpG 1018 adjuvant, serves hospitals, DOD, and retail outlets, while Phase 2 plague and Phase 1/2 shingles candidates expand its pipeline.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 405
HQ: EmeryVille

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
DVAX	Dynavax Technologies Corp. Cap: 1.8B	EQUITY	NCM	USD	US2681582019	Active	📈